The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
Top Cited Papers
Open Access
- 10 March 2011
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 117 (10), 2807-2812
- https://doi.org/10.1182/blood-2010-11-314708
Abstract
Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-HodKeywords
This publication has 30 references indexed in Scilit:
- Histone Deacetylase Inhibitors Activate NF-κB in Human Leukemia Cells through an ATM/NEMO-related PathwayJournal of Biological Chemistry, 2010
- Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphomaCancer, 2009
- Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphomaLeukemia & Lymphoma, 2009
- Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cellsBlood, 2009
- Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphomaBlood, 2009
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood, 2005
- New Treatment Options Have Changed the Survival of Patients With Follicular LymphomaJournal of Clinical Oncology, 2005
- Improved Survival of Follicular Lymphoma Patients in the United StatesJournal of Clinical Oncology, 2005
- Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2005